Research Analysts Offer Predictions for iBio Q3 Earnings

iBio, Inc. (NYSE:IBIO) – Investment analysts at Brookline Capital Acquisition increased their Q3 2026 EPS estimates for shares of iBio in a report issued on Wednesday, February 11th. Brookline Capital Acquisition analyst K. Dolliver now anticipates that the company will earn ($0.07) per share for the quarter, up from their previous forecast of ($0.08). The consensus estimate for iBio’s current full-year earnings is ($1.74) per share. Brookline Capital Acquisition also issued estimates for iBio’s Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.34) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.32) EPS.

A number of other equities analysts have also weighed in on the stock. Chardan Capital reiterated a “buy” rating and issued a $5.00 price target on shares of iBio in a report on Thursday, February 12th. Oppenheimer reaffirmed an “outperform” rating on shares of iBio in a research report on Wednesday, October 29th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $4.00.

iBio Price Performance

iBio stock opened at $2.29 on Monday. iBio has a 1 year low of $0.56 and a 1 year high of $6.89. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.76 and a current ratio of 1.76. The firm has a 50 day moving average price of $2.17 and a 200 day moving average price of $1.41. The company has a market cap of $79.11 million, a price-to-earnings ratio of -2.29 and a beta of 1.26.

Hedge Funds Weigh In On iBio

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Logos Global Management LP purchased a new position in iBio in the 4th quarter worth approximately $3,860,000. ADAR1 Capital Management LLC lifted its position in shares of iBio by 1,402.0% during the fourth quarter. ADAR1 Capital Management LLC now owns 405,531 shares of the company’s stock worth $783,000 after purchasing an additional 378,531 shares in the last quarter. Persistent Asset Partners Ltd purchased a new position in shares of iBio in the fourth quarter valued at $76,000. Frazier Life Sciences Management L.P. acquired a new stake in iBio during the 4th quarter valued at $3,770,000. Finally, Marshall Wace LLP acquired a new stake in iBio during the 4th quarter valued at $234,000. 7.90% of the stock is owned by institutional investors and hedge funds.

About iBio

iBio, Inc (NYSE: IBIO) is a biotechnology company that develops and manufactures plant-based biologics, including vaccines and therapeutic proteins. Leveraging proprietary technology derived from Nicotiana benthamiana, a relative of tobacco, iBio applies a molecular farming approach to produce complex proteins more rapidly and with greater scalability than traditional cell-culture methods. The company’s core expertise lies in its ability to design, express and purify recombinant proteins for both research and commercial applications.

Central to iBio’s operations is the iBio CDM™ (cGMP-Direct Manufacture) platform, an integrated system that enables end-to-end development and production of biologics.